Cover Image
Market Research Report

Global Cardiomyopathy Therapies Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 756739
Published Content info 108 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Cardiomyopathy Therapies Market 2019-2023
Published: December 3, 2018 Content info: 108 Pages
Description

About this market:

Advent of genomic medicine to push market growth during the forecast period. Cardiomyopathy is one of the major causes of heart failure. Genomic medicine is an emerging field in healthcare, it uses gene-related information of an individual. Technavio's analysts have predicted that the cardiomyopathy therapies market will register a CAGR of almost 2% by 2023.

Market Overview:

Initiative to increase awareness about disease

There has been an increase in initiatives to spread awareness about cardiomyopathy among people in the last few years.

High cost of treatment

Cardiomyopathy makes it difficult for the heart to pump blood to rest of the body. The condition can be treated by surgically implanting devices within the heart, these devices are quite expensive. This high cost associated with the treatment of cardiomyopathy may pose a challenge to the market.

For the detailed list of factors that will drive and challenge the growth of the cardiomyopathy therapies market during the 2019-2023, view our report.

Competitive Landscape:

The market appears to be moderately concentrated and with the presence of several companies including Merck and Sanofi the competitive environment is quite intense. Factors such as the advent of genomic medicine and the initiative to increase awareness about disease, will provide considerable growth opportunities to cardiomyopathy therapies manufactures. AstraZeneca, Merck, Pfizer, and Sanofi are some of the major companies covered in this report.

Table of Contents
Product Code: IRTNTR30336

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

  • Pipeline analysis

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Dilated cardiomyopathy - Market size and forecast 2018-2023
  • Hypertrophic cardiomyopathy - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product

PART 10: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • Market trends

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Merck
  • Pfizer
  • Sanofi

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Years in consideration
  • Exhibit 02: Global CVD treatment market
  • Exhibit 03: Segments of global CVD treatment market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Pipeline drugs in late-stage clinical trials
  • Exhibit 07: Market definition - Inclusions and exclusions checklist
  • Exhibit 08: Market size 2018
  • Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 11: Five forces analysis 2018
  • Exhibit 12: Five forces analysis 2023
  • Exhibit 13: Threat of rivalry
  • Exhibit 14: Market condition - Five forces 2018
  • Exhibit 15: Type - Market share 2018-2023 (%)
  • Exhibit 16: Comparison by type
  • Exhibit 17: Dilated cardiomyopathy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 18: Dilated cardiomyopathy - Year-over-year growth 2019-2023 (%)
  • Exhibit 19: Hypertrophic cardiomyopathy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Hypertrophic cardiomyopathy - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Market opportunity by type
  • Exhibit 24: Customer landscape
  • Exhibit 25: Market share by geography 2018-2023 (%)
  • Exhibit 26: Geographic comparison
  • Exhibit 27: Americas - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 28: Americas - Year-over-year growth 2019-2023 (%)
  • Exhibit 29: EMEA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: EMEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: APAC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Key leading countries
  • Exhibit 34: Market opportunity
  • Exhibit 35: Decision framework
  • Exhibit 36: Impact of drivers and challenges
  • Exhibit 37: Vendor landscape
  • Exhibit 38: Landscape disruption
  • Exhibit 39: Vendors covered
  • Exhibit 40: Vendor classification
  • Exhibit 41: Market positioning of vendors
  • Exhibit 42: AstraZeneca - Vendor overview
  • Exhibit 43: AstraZeneca - Business segments
  • Exhibit 44: AstraZeneca - Organizational developments
  • Exhibit 45: AstraZeneca - Geographic focus
  • Exhibit 46: AstraZeneca - Key offerings
  • Exhibit 47: Merck - Vendor overview
  • Exhibit 48: Merck - Business segments
  • Exhibit 49: Merck - Organizational developments
  • Exhibit 50: Merck - Segment focus
  • Exhibit 51: Merck - Key offerings
  • Exhibit 52: Pfizer - Vendor overview
  • Exhibit 53: Pfizer - Business segments
  • Exhibit 54: Pfizer - Organizational developments
  • Exhibit 55: Pfizer - Geographic focus
  • Exhibit 56: Pfizer - Segment focus
  • Exhibit 57: Pfizer - Key offerings
  • Exhibit 58: Sanofi - Vendor overview
  • Exhibit 59: Sanofi - Business segments
  • Exhibit 60: Sanofi - Organizational developments
  • Exhibit 61: Sanofi - Segment focus
  • Exhibit 62: Sanofi - Key offerings
  • Exhibit 63: Validation techniques employed for market sizing
  • Exhibit 64: List of abbreviations
Back to Top